Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E4JL | ISIN: FR001400MDW2 | Ticker-Symbol: D08
Frankfurt
22.01.25
20:45 Uhr
30,300 Euro
+1,700
+5,94 %
Branche
Maschinenbau
Aktienmarkt
Sonstige
1-Jahres-Chart
STIF SA Chart 1 Jahr
5-Tage-Chart
STIF SA 5-Tage-Chart
RealtimeGeldBriefZeit
29,50030,20022.01.
Actusnews Wire
159 Leser
Artikel bewerten:
(1)

STIF: Stif: Consolidated annual Turnover 2024: + 72,3%

Finanznachrichten News
PRESS RELEASE

Consolidated annual Turnover 2024: + 72,3%

Strong growth driven by ramp-up of BESS business

Saint-Georges-sur-Loire, January 22, 2025 - 5:45 pm - STIF (FR001400MDW2, ALSTI), expert in explosion protection, publishes its consolidated annual turnover for the 2024 financial year, ending December 31.

In €m2024
(12 months)
2023
(12 months)
Change

Turnvover

61,2

35,5

+ 72,3%

Consolidated sales for the STIF group amounted to €61.2 million for the full 2024 financial year, up +72.3% on the 2023 figure.

As previously announced, this strong growth reflects the ramp-up in sales of products dedicated to the protection of BESS (Battery Energy Storage System). In this segment, STIF recorded sales of €29.3 million in 2024, compared with €4.5 million in 2023. This represents 47.8% of the Group's total sales to the end of 2024.

The commercial success with several of the world's leading players in BESS energy storage, first with TESLA and SUNGROW, then with NIDEC, CATL and BYD in the second half of the year, was accompanied by a very significant increase in sales volumes in 2024. These are set to continue on a strong growth trajectory in the years ahead.

In addition, sales of products to protect against explosions in industrial environments are benefiting from a highly innovative offering and geographic coverage of several high-potential regions. Sales in this business came to €10.8 million in 2024, compared with €10.0 million a year earlier, representing 17.7% of 2024 sales. The launch of Vigiflam Vi (flameless discharge panel) at the end of 2024 will fuel growth in this business from 2025.

The Group's historic ranges of bulk handling equipment recorded a slight increase in sales of 2.8% to €19.4 million in 2024 (€18.9 million in 2023). In a sluggish market, STIF benefits from its broad customer base and internationally recognized expertise in this segment.

Outside France, stronger positions in both North America and Asia

STIF France accounts for 84% of Group sales, with €51.5 million, mainly driven by international sales, particularly to the United States (49% of sales in 2024) and Asia (12% of sales in 2024).

Sales to the United States increased 3.6-fold between 2023 and 2024, reaching €29.8 million in 2024 versus €8.2 million in 2023.

The new production unit based in Texas is designed to serve this highly promising North American market, in phase with the accelerating commercialization of high value-added BESS products.

Asian subsidiaries reported total sales of €7.1 million in 2024, compared with €5.1 million a year earlier, an increase of 40.9% boosted by sales by the Vigilex Energy division to SUNGROW in particular. It should be noted that the Group's commercial relationship with SUNGROW will benefit in 2025 from both business volumes initially planned for 2024 and significant additional orders.

Solid growth prospects to 2027

Positioned in a market segment that is growing exponentially, and with steadily expanding geographical coverage, STIF confirms its ambition to achieve sales of around €80 million by 2027, with EBITDA exceeding 20% of sales.

Next Meeting

Publication of 2024 annual results: March 27, 2025

SFAF Investor Meeting: April 2nd, 2025 - 10:00 am

Annual Shareholders' Meeting: May 22nd, 2025

STIF, the explosion protection specialist

Founded in 1984, the STIF Group is a French industrial player specializing in the design, manufacturing and marketing of innovative industrial equipment intended for niche markets. Historically positioned in handling equipment for bulk products, such as elevator buckets, elevator belts and compression couplings, the family group has diversified over the last ten years by developing in the field of protection passive against the risks of industrial dust explosions, and since 2022 in the activity of protection against the risks of explosion of battery energy storage systems (BESS). With 227 employees, internationally referenced and recognized product ranges, 4 factories spread between France and Asia, and in the USA, the Group intends to take a leading position in this sector directly linked to the market. exponential growth of renewable energies

Contacts

STIF
External Relations

Géraldine Baudouin
direction@stifnet.com
02 41 72 16 83
SEITOSEI.ACTIFIN
Investor Relations

Ghislaine Gasparetto
stif@actifin.fr
01 56 88 11 22
SEITOSEI.ACTIFIN
Press Relations

Michael Scholze
michael.scholze@seitosei-actifin.com
01 56 88 11 14
------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: lWmdlZ2Zl2ycmW1uap5qaWNpmGhplWTGmZfLmmqbl5mcnJuWlmyWmMmWZnFqm2hr
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-89635-20250122_stif_pr-turnover-2024-vfinal.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2025 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.